Literature DB >> 164351

Lipoprotein of the density 1.006-1.020 in the plasma of patients with type III hyperlipoproteinaemia in the postabsorptive state.

J R Patsch.   

Abstract

Using a rate zonal ultracentrifugal technique in 10 patients with type III hyperlipoproteinaemia, very low density lipoproteins (VLDL) (d less than 1.006, S(f) greater than 20), an intermediate lipoprotein density class with a S(f) range of 15 - 20 (Lp III), and low density lipoproteins (LDL) (S(f) 6 - 8) could be isolated from the plasma. The Lp III was found as a symmetrical peak between VLDL and LDL; its plasma concentration was 248 mg/100 ml plasma (mean), 92 - 469 mg/100 ml plasma (range); the Lp III/LDL ratio was 0.65 (mean), 0.25 - 2.3 (range); the chemical composition w/w was 35.8 percent total cholesterol, 19.3 percent triglycerides, 24.3 percent phospholipids, and 20.4 percent protein (mean). In agarose gel electrophoresis, the Lp III migrated faster than LDL, but slower than VLDL. By means of a double immunodiffusion technique and immunoelectrophoresis, apo-Lp B and apo-Lp C were detectable. In an angle head rotor at 1.4 x 10-8 g. min. Lp III can be separated from VLDL at a solvent density of 1.006, and from LDL at a density of 1.025. In the postabsorptive state in one patient with type I hyperlipoproteinaemia, five with type II and 20 with type IV, and in 50 healthy persons of both sexes, this Lp III peak was not found. The finding of a high concentration of Lp III and a rather low concentration of LDL in the plasma of patients with type III hyperlipoproteinaemia can be regarded as further evidence for an impaired catabolism of VLDL to LDL at Lp III ("intermediate" lipoprotein).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 164351     DOI: 10.1111/j.1365-2362.1975.tb00427.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Evidence for the lipoprotein heterogeneity of human plasma high density lipoproteins isolated by three different procedures.

Authors:  A Suenram; W J McConathy; P Alaupovic
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

2.  Evaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia.

Authors:  J R Patsch; R L Jackson; A M Gotto
Journal:  Klin Wochenschr       Date:  1977-11-01

3.  Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.

Authors:  S H Gianturco; A M Gotto; R L Jackson; J R Patsch; H D Sybers; O D Taunton; D L Yeshurun; L C Smith
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

4.  Activation of adipose tissue lipoprotein lipase by lipoprotein fractions from normals and patients with type v hyperlipoproteinemia.

Authors:  H J Lisch; W Patsch; L Riedler; S Sailer; H Braunsteiner
Journal:  Klin Wochenschr       Date:  1978-11-01

5.  Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities.

Authors:  G Miesenböck; B Hölzl; B Föger; E Brandstätter; B Paulweber; F Sandhofer; J R Patsch
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

6.  Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.

Authors:  C J Packard; A Munro; A R Lorimer; A M Gotto; J Shepherd
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.